INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 78 filers reported holding INOZYME PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,452 | -50.4% | 8,441 | -34.3% | 0.00% | – |
| Q2 2023 | $71,519 | +7468.1% | 12,840 | +7681.8% | 0.00% | – |
| Q1 2023 | $945 | +455.9% | 165 | +1.9% | 0.00% | – |
| Q4 2022 | $170 | – | 162 | +3.2% | 0.00% | – |
| Q3 2022 | $0 | -100.0% | 157 | -11.3% | 0.00% | – |
| Q2 2022 | $1,000 | -91.7% | 177 | -94.0% | 0.00% | – |
| Q1 2022 | $12,000 | -77.8% | 2,955 | -63.0% | 0.00% | – |
| Q4 2021 | $54,000 | +5300.0% | 7,983 | +16531.2% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 48 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | -97.1% | 48 | -97.2% | 0.00% | – |
| Q1 2021 | $34,000 | -83.0% | 1,703 | -82.4% | 0.00% | – |
| Q4 2020 | $200,000 | +24.2% | 9,696 | +58.6% | 0.00% | – |
| Q3 2020 | $161,000 | – | 6,113 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 1,009,117 | $26,529,000 | 9.44% |
| YALE UNIVERSITY | 113,502 | $2,984,000 | 9.13% |
| Sofinnova Investments, Inc. | 2,028,308 | $53,324,000 | 3.95% |
| Novo Holdings A/S | 2,569,379 | $67,549,000 | 3.35% |
| NEA Management Company, LLC | 2,444,379 | $64,263,000 | 2.72% |
| RA Capital Management | 2,003,653 | $52,676,000 | 0.96% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,150,299 | $30,241,000 | 0.74% |
| Rock Springs Capital Management LP | 879,954 | $23,134,000 | 0.59% |
| SPHERA FUNDS MANAGEMENT LTD. | 196,411 | $5,164,000 | 0.51% |
| Orbimed Advisors | 400,400 | $10,527,000 | 0.13% |